1. Home
  2. RAND vs CVM Comparison

RAND vs CVM Comparison

Compare RAND & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

N/A

Current Price

$11.47

Market Cap

30.6M

Sector

Finance

ML Signal

N/A

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

N/A

Current Price

$1.48

Market Cap

30.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RAND
CVM
Founded
1969
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.6M
30.1M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
RAND
CVM
Price
$11.47
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.6K
201.4K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
10.83%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.57
N/A
Revenue Growth
N/A
65.45
52 Week Low
$10.00
$0.89
52 Week High
$17.49
$13.48

Technical Indicators

Market Signals
Indicator
RAND
CVM
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
RAND
CVM

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: